ARGENX SE

FORWARD LOOKING STATEMENTS

The contents of this announcement include statements that are, or may be deemed to be, “forward-looking statements.” These forward-looking statements can be identified by the use of forward-looking terminology, including the terms “advance,” “aim,” “build,” “commit,” “continue,” “potential,” and “will,” and include statements argenx makes concerning its plan to present new data at 2026 AAN Annual Meeting (including new data supporting broader VYVGART use across MG and CIDP); study results that build on VYVGART’s approved gMG indication and show its potential as the first and only biologic therapy effective across MG subtypes; its commitment to improving the lives of people suffering from severe autoimmune diseases; presentations that will highlight new data for adimanebart in CMS and argenx’s broader neuromuscular pipeline, including Phase 3 programs evaluating empasiprubart in CIDP; its motivation to advance the impact of MG and CIDP treatment; its goal to expand VYVGART’s reach to as many patients living with MG as possible, regardless of subtype; the potential for VYVGART Hytrulo to deliver early clinical improvement in treatment-naïve CIDP patients; the planned supplemental Biologics License Application (sBLA) submission to the U.S. Food and Drug Administration (FDA) to expand the VYVGART label into oMG; FDA review of the VYVGART sBLA submission for the treatment of AChR-Ab seronegative gMG; two Phase 3 CIDP studies that highlight its commitment to advancing innovative treatment options across all adult CIDP patient populations with empasiprubart; and results that build on the previously presented proof-of-concept data and further support adimanebart in CMS. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. argenx’s actual results may differ materially from those predicted by the forward-looking statements as a result of various important factors, including but not limited to, the results of argenx’s clinical trials; expectations regarding the inherent uncertainties associated with the development of novel drug therapies; preclinical and clinical trial and product development activities and regulatory approval requirements; the acceptance of its products and product candidates by its patients as safe, effective and cost-effective; the impact of governmental laws and regulations, including tariffs, export controls, sanctions and other regulations on its business; its reliance on third-party suppliers, service providers and manufacturers; inflation and deflation and the corresponding fluctuations in interest rates; and regional instability and conflicts. A further list and description of these risks, uncertainties and other risks can be found in argenx’s U.S. Securities and Exchange Commission (SEC) filings and reports, including in argenx’s most recent annual report on Form 20-F filed with the SEC as well as subsequent filings and reports filed by argenx with the SEC. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. argenx undertakes no obligation to publicly update or revise the information in this press release, including any forward-looking statements, except as may be required by law.